[
  {
    "ts": null,
    "headline": "Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings",
    "summary": "MOH's Q2 revenues are set to rise nearly 10%, but rising costs cloud its profit outlook.",
    "url": "https://finnhub.io/api/news?id=7e425f1647e4d45445e854a79d68d35beff6b6d5f5f4a1108b9ebe3308173ee0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752854580,
      "headline": "Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings",
      "id": 136007914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "MOH's Q2 revenues are set to rise nearly 10%, but rising costs cloud its profit outlook.",
      "url": "https://finnhub.io/api/news?id=7e425f1647e4d45445e854a79d68d35beff6b6d5f5f4a1108b9ebe3308173ee0"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Hold Accuray Stock in Your Portfolio for Now",
    "summary": "ARAY rides strong global demand and CyberKnife momentum, but order declines and backlog pressure temper the outlook.",
    "url": "https://finnhub.io/api/news?id=3c3091a28cb96c0c472f5692be811b28cc3d1a62f1d6e81757062ed30fa45034",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752848760,
      "headline": "Here's Why You Should Hold Accuray Stock in Your Portfolio for Now",
      "id": 136006857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "ARAY rides strong global demand and CyberKnife momentum, but order declines and backlog pressure temper the outlook.",
      "url": "https://finnhub.io/api/news?id=3c3091a28cb96c0c472f5692be811b28cc3d1a62f1d6e81757062ed30fa45034"
    }
  },
  {
    "ts": null,
    "headline": "Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
    "url": "https://finnhub.io/api/news?id=fb0a91fe72e99e1e2b7983bb926c9375874cdaae59d2cf97db783c99d91dd933",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752844502,
      "headline": "Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS",
      "id": 136005771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
      "url": "https://finnhub.io/api/news?id=fb0a91fe72e99e1e2b7983bb926c9375874cdaae59d2cf97db783c99d91dd933"
    }
  }
]